Sumitomo Dainippon Pharma Co (DPM) Financial Statements
Sumitomo Dainippon Pharma Co Financial Overview
Sumitomo Dainippon Pharma Co's market cap is currently $4.80B. The company's EPS TTM is $277.11; its P/E ratio is 6.74; Sumitomo Dainippon Pharma Co is estimated to report earnings on January 29, 2027, and the estimated EPS forecast is $0.62. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 398.83B | $ 453.29B | $ 314.56B | $ 555.54B | $ 560.03B |
| Gross Profit | $ 225.38B | $ 256.89B | $ 157.08B | $ 342.95B | $ 371.18B |
| Operating Income | $ 22.42B | $ 50.34B | $ -1.48B | $ 11.20B | $ 56.55B |
| EBITDA | $ 51.73B | $ 131.32B | $ -281.07B | $ -3.50B | $ 124.36B |
| Net Income | $ 23.63B | $ 106.86B | $ -314.97B | $ -74.51B | $ 56.41B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 23.12B | $ 44.31B | $ 29.05B | $ 143.48B | $ 202.98B |
| Total Assets | $ 742.60B | $ 804.57B | $ 907.51B | $ 1.13T | $ 1.31T |
| Total Debt | $ 314.25B | $ 217.19B | $ 427.86B | $ 346.37B | $ 284.54B |
| Net Debt | $ 291.13B | $ 172.88B | $ 398.82B | $ 202.89B | $ 81.56B |
| Total Liabilities | $ 573.13B | $ 512.10B | $ 751.37B | $ 727.96B | $ 634.44B |
| Stockholders' Equity | $ 169.48B | $ 292.47B | $ 156.06B | $ 406.75B | $ 607.89B |
| Cash Flow | |||||
| Free Cash Flow | $ 8.00B | $ 67.11B | $ -252.66B | $ 3.47B | $ 23.89B |
| Operating Cash Flow | $ 16.50B | $ 71.72B | $ -241.89B | $ 11.94B | $ 31.24B |
| Investing Cash Flow | $ 99.75B | $ 22.55B | $ 33.04B | $ -145.99B | $ -21.91B |
| Financing Cash Flow | $ -108.84B | $ -91.27B | $ 77.85B | $ 51.59B | $ -17.79B |
Currency in JPY
